Acute Myeloid Leukemia
![[object Object]](https://eu-images.contentstack.com/v3/assets/blte6dbc6ba360422d5/blt9cfe126f2fbf497a/60c865ee9dba9d79d6561192/slider.jpg?width=1920&height=389&format=webp&quality=50)
I see Acute Myeloid Leukemia
Welcome to ‘I see Acute Myeloid Leukemia’, a dedicated resource to help healthcare practitioners find the latest information about the signs, symptoms and diagnoses of AML.
What is Acute Myeloid Leukemia?
Acute myeloid leukemia (AML) is the most common acute leukemia in adults.[1] The diagnosis is established by the presence of 20% or more blasts of myeloid origin in the bone marrow or peripheral blood.[1]
Figure 1: Annual number of AML cases in the UK, stratified by age group.[2]
Disease incidence by age
AML is primarily a disease that affects people of advanced age: the median age at diagnosis is around 65 years.[1][2]
Figure 2: Distribution of AML sub-types according to age group.[3]
Disease distribution by subtype in Sweden
Most patients are diagnosed with de novo AML, i.e. without a clinical history of any myeloproliferative disease or leukemogenic therapy. AML with an antecedent hematological disease (AHD) and therapy-related AML (t-AML) are less frequently (<25%) seen at diagnosis.[3]
Figure 3: Percentage of patients with high-risk cytogenetic profile in different AML subgroups.[3]
High-risk cytogenetic profile according subgroups
Adverse prognostic cytogenetic anomalies are especially present in advanced disease or in patients with antecedent hematological disease (AHD-AML) or therapy-related AML (tAML).
Janssen Hematology
More information across the spectrum of blood cancers.
